The biosensor is suitable for deployment on smart, compact devices for drug discovery, molecular diagnostics and sequencing
With the introduction of the first molecular electronics chip, the Roswell Molecular Electronics (ME) Platform, its developer Roswell Biotechnologies, a molecular electronics company, intends to introduce a new way for performing functions related to biosensing.
“As a universal, programmable biosensor, the Roswell ME Platform opens a new era of digitising biology, just as the first microprocessor opened the era of digitising information,” said Paul Mola, Roswell Biotechnologies’ founder, CEO and president.
The Roswell ME Platform integrates single molecules into electronic circuits, acting as sensor elements to create the first fully scaled biosensors on standard semiconductor chips that can translate the dynamic process of molecular interactions into electrical measurements in real-time.
The sensor targets are programmed according to the particular molecule wired into the chip, providing for a programmable and universal biosensor platform. This new kind of single-molecule measurement with a resolution for individual binding events enables an unprecedented and information-rich view of biology for scalability in a broad range of applications deployed on smart, compact devices.
The Roswell ME Platform is being developed for applications in drug discovery, molecular diagnostics, and sequencing.
“Innovation in drug discovery is fueled by new views of how molecules interact and new ways to increase the scale of molecular screening,” said Dhaval Patel, PhD, executive
vice president and chief scientific officer of UCB, a global pharmaceutical company. “The Roswell ME Platform has the unique potential to address both these areas with its new
molecular biosensor chip. This represents the type of deep technological advance that could accelerate the discovery of new medicines.”
“The bold goal of curing all disease this century will require both fundamental advances in understanding biology and new technologies to support personal health and wellness,” said Sandra Schmid, PhD, Chan Zuckerberg Biohub chief scientific officer, and Roswell Scientific Advisory Board member. “The Roswell ME Platform offers new power to address our understanding of molecular interactions as well as ways to make this information widely accessible.”
